Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.

Inclusion Criteria:

• Age > 18 years of age as of start of treatment with BLENREP
• Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
• Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
• Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.

Exclusion Criteria:

• Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
• Age > 89 years of age as of start of index therapy